147 related articles for article (PubMed ID: 22944561)
1. Case of polycythemia vera concurrent with FIP1L1-PDGFRA-positive myeloproliferative neoplasm with eosinophilia.
Alrwas A; Quesada JR; Marcos LA; Mehta SS; Shattuck BL; Nguyen ND; Juneja HS
Cancer Genet; 2012 Oct; 205(10):519-22. PubMed ID: 22944561
[TBL] [Abstract][Full Text] [Related]
2. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
Rathe M; Kristensen TK; Møller MB; Carlsen NL
Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
[TBL] [Abstract][Full Text] [Related]
3. Complete response of myeloid sarcoma with FIP1L1-PDGFRA -associated myeloproliferative neoplasms to imatinib mesylate monotherapy.
Tang TC; Chang H; Chuang WY
Acta Haematol; 2012; 128(2):83-7. PubMed ID: 22722648
[TBL] [Abstract][Full Text] [Related]
4. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
Metzgeroth G; Walz C; Score J; Siebert R; Schnittger S; Haferlach C; Popp H; Haferlach T; Erben P; Mix J; Müller MC; Beneke H; Müller L; Del Valle F; Aulitzky WE; Wittkowsky G; Schmitz N; Schulte C; Müller-Hermelink K; Hodges E; Whittaker SJ; Diecker F; Döhner H; Schuld P; Hehlmann R; Hochhaus A; Cross NC; Reiter A
Leukemia; 2007 Jun; 21(6):1183-8. PubMed ID: 17377585
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome.
Pardanani A; D'Souza A; Knudson RA; Hanson CA; Ketterling RP; Tefferi A
Leukemia; 2012 Nov; 26(11):2439-41. PubMed ID: 22705991
[No Abstract] [Full Text] [Related]
6. [FIP1L1-PDGFRalpha-positive myeloproliferative disease with hypereosinophilia: clinical characteristics and pathogenetic therapy].
Nemchenko IS; Khoroshko ND; Turkina AG; Sokolova MA; Kokhno AV; Semenova EA; Zakharova AV
Ter Arkh; 2005; 77(7):90-2. PubMed ID: 16116920
[No Abstract] [Full Text] [Related]
7. [Clonal eosinophilia revealed by recurrent Staphylococcus aureus infection].
Vandenbos F; Figueredo M; Dumon-Gubeno MC; Nicolle I; Tarhini A; Medioni LD; Naman H; Mouroux J
Rev Pneumol Clin; 2011 Jun; 67(3):167-9. PubMed ID: 21665081
[TBL] [Abstract][Full Text] [Related]
8. [Myeloproliferative hypereosinophilic syndrome revealed by bipolar mucosal ulcerations].
Isvy-Joubert A; Hickman G; Flageul B; Battistella M; Bagot M; Galicier L; Petit A
Ann Dermatol Venereol; 2012 Oct; 139(10):636-40. PubMed ID: 23122377
[TBL] [Abstract][Full Text] [Related]
9. Atypical Phenotype and Treatment Response Pattern in a Patient with FIP1L1-PDGFRα Mutation.
Bikhchandani M; Johnson R; Tuan B; Tefferi A
Acta Haematol; 2018; 140(2):67-70. PubMed ID: 30184522
[TBL] [Abstract][Full Text] [Related]
10. A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement.
Coltro G; Santi R
Blood; 2023 May; 141(20):2541. PubMed ID: 37200055
[No Abstract] [Full Text] [Related]
11. [The efficacy of imatinib mesylate for patients with myeloproliferative neoplasm (MPN) with eosinophilia].
Zhang Y; Qin TJ; Zhou CL; Liu L; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2009 Jun; 30(6):381-4. PubMed ID: 19951530
[TBL] [Abstract][Full Text] [Related]
12. Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation.
Pardanani A; Lasho T; Barraco D; Patnaik M; Elala Y; Tefferi A
Am J Hematol; 2016 Mar; 91(3):E10-1. PubMed ID: 26663400
[No Abstract] [Full Text] [Related]
13. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
[TBL] [Abstract][Full Text] [Related]
14. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.
Pardanani A; Ketterling RP; Li CY; Patnaik MM; Wolanskyj AP; Elliott MA; Camoriano JK; Butterfield JH; Dewald GW; Tefferi A
Leuk Res; 2006 Aug; 30(8):965-70. PubMed ID: 16406016
[TBL] [Abstract][Full Text] [Related]
15. A case of myeloid neoplasm with FIP1L1-PDGFRA rearrangement without marked peripheral blood eosinophilia.
Wang J; Zhang Q; Zeng H; Chen B; Ouyang J
Pharmacogenomics; 2016; 17(2):99-102. PubMed ID: 26666578
[TBL] [Abstract][Full Text] [Related]
16. Charcot-Leyden crystals in the trephine biopsy of a patient with a FIP1L1-PDGFRA - positive myeloproliferative disorder.
Lyall H; O'Connor S; Clark D
Br J Haematol; 2007 Aug; 138(4):405. PubMed ID: 17593250
[No Abstract] [Full Text] [Related]
17. Myeloid neoplasm with rearrangement of PDGFRA, but with no significant eosinophilia: should we broaden the World Health Organization definition of the entity?
Rudzki Z; Giles L; Cross NC; Lumley M
Br J Haematol; 2012 Mar; 156(5):558. PubMed ID: 22224867
[No Abstract] [Full Text] [Related]
18. Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.
Helbig G; Kyrcz-Krzemien S
Leuk Lymphoma; 2013 Apr; 54(4):897-8. PubMed ID: 23025324
[No Abstract] [Full Text] [Related]
19. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia.
von Bubnoff N; Sandherr M; Schlimok G; Andreesen R; Peschel C; Duyster J
Leukemia; 2005 Feb; 19(2):286-7. PubMed ID: 15618966
[No Abstract] [Full Text] [Related]
20. Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.
Miyazawa K; Kakazu N; Ohyashiki K
Int J Hematol; 2007 Jan; 85(1):5-10. PubMed ID: 17261495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
